Eli Lilly (LLY) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients lose up to 20% of their weight in a mid-stage trial involving obese or overweight people without diabetes.
Based on a per-protocol analysis of data from a Phase 2 trial for the once-weekly injectable, the Indiana-based drugmaker said eloralintide caused average weight reductions from 9.5% to 20.1%, while the placebo group experienced an average weight loss of 0.4%.
The 48-week trial enrolled 263 obese or overweight patients with one or more weight-related conditions but without type 2 diabetes. As its primary objective, the U.S.-based study was designed to evaluate eloralintide’s superiority against placebo in causing percentage body weight reduction.
Regarding safety, the maker of Zepbound weight-loss therapy said that mild to moderate gastrointestinal symptoms and fatigue were the most common adverse events linked to eloralintide.
The company expects to advance eloralintide into Phase 3 development later this year to evaluate it as a single agent for obesity. The data readout was published in The Lancet and also presented at the ongoing ObesityWeek 2025 in Atlanta, GA.